People with suspected Mpox should isolate while awaiting testing results and if confirmed positive, continue isolation until all lesions are healed or criteria are met per the CDPH MPox Home Isolation Guidance for the General Public.
Supportive care and treatment of symptoms should be initiated for all patients with suspected MPox infection. This may include topical medicines or other clinical interventions to manage symptoms with particular focus on management of pain and pruritis. Please see NYC Health treatment guidance and CDC resources below.
Tecovirimat (also called TPOXX), an antiviral medication available through an expanded access Investigational New Drug (EA-IND) protocol for the treatment of MPox infection, is available—see ordering information below.
Providers should consider tecovirimat treatment for high-risk suspect cases who have pending lab testing results and suspect cases who are experiencing severe symptoms.
Antiviral treatment of MPox infection should be considered for people with severe infection, illness complications (including pain not controlled with supportive care), and risk factors for progression to severe infection (children <8 years of age, immunocompromised or pregnant people, or those with a history of atopic dermatitis or eczema). Antiviral treatment (such as with TPOXX) should not be considered a substitute for pain management.
CDC TPOXX Required Paperwork
To place an order for TPOXX, please fill out the linked TPOXX Resource Request Form and CDPH’s TPOXX Request and Data Collection Form and email it to email@example.com. A member of our team will confirm receipt of your request and begin processing your order. Orders will be shipped directly to the address listed on your resource request form. Please note, the CDC required TPOXX paperwork must be completed within seven (7) days of TPOXX treatment initiation.